Prescribing SYMBYAX

SYMBYAX (olanzapine/fluoxetine HCl) is the only antidepressant approved by the FDA for bipolar depression. In preclinical studies, SYMBYAX increased all three neurotransmitters that are important in the treatment of bipolar depression: serotonin, dopamine and norepinephrine.¹

1. Zhang W, et al. Neuropsychopharmacol. 2000;23:250-262.

SYMBYAX is a powerful bipolar depression treatment in one pill that is:

Effective
Simple
Reliable Safety

Effective: Improves symptoms as early as week 1

SYMBYAX improves depressive symptoms as early as week 1.

†Treatment arm numbers as of week 1.

Improvement in Montgomery–Asberg Depression Rating Scale (MADRS) Total Score for the SYMBYAX group was statistically greater than placebo at weeks 1, 3, 4, 6, and 8 in pooled studies.¹

Individual study results: In one study, SYMBYAX was superior to placebo at weeks 1, 4, 6, and 8; in the other study, SYMBYAX was superior to placebo at every visit.

Results were calculated on the basis of a visitwise LOCF‡ analysis of mean improvement from baseline in MADRS Total Scores. These data do not imply specific onset of action in individual patients.

Olanzapine is not approved for the treatment of bipolar depression.

1. Data on file, Lilly Research Laboratories.
‡ LOCF is Last Observation Carried Forward.

Simple for Clinician and Patient

A powerful treatment for bipolar depression in one pill
Therapeutic dose can be used from day 1 - no titration necessary
Requires a single copay under most healthcare plans
Available in four convenient dosage options:
5 mg/25 mg, 6 mg/50 mg, 12 mg/25 mg, and 12 mg/50 mg
(3 mg/25 mg olanzapine/fluoxetine HCl capsules)
Only antidepressant approved by the FDA for bipolar depression

Reliable Safety

Overall, the SYMBYAX (olanzapine/fluoxetine HCl) safety profile is similar to that of its individual components. SYMBYAX patients had no statistically greater risk of treatment-emergent mania than patients taking placebo. In patients with bipolar depression, a manic episode is a potential consequence of treatment with a conventional antidepressant alone. Because of the cyclical nature of bipolar disorder, patients should be monitored closely for the development of symptoms of mania/hypomania during treatment with SYMBYAX.

Reference:
1. Zhang W et al. Neuropsyhopharmacol. 2000;23:260-262.

NOTE: To view or print PDF files, you must have Adobe® Reader®. Click here to download the free reader.